Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -54.10% | 71.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -54.10% | 71.03% | |||
| Cost of Revenue | -98.32% | -28.89% | |||
| Gross Profit | 133.05% | 51.26% | |||
| SG&A Expenses | 39.20% | -46.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.17% | -22.41% | |||
| Operating Income | 3.46% | 23.86% | |||
| Income Before Tax | 33.20% | 20.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.20% | 20.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.20% | 20.45% | |||
| EBIT | 3.46% | 23.86% | |||
| EBITDA | 3.48% | 24.00% | |||
| EPS Basic | 58.00% | 30.65% | |||
| Normalized Basic EPS | 57.88% | 21.97% | |||
| EPS Diluted | 58.00% | 30.65% | |||
| Normalized Diluted EPS | 57.88% | 21.97% | |||
| Average Basic Shares Outstanding | 59.07% | 14.71% | |||
| Average Diluted Shares Outstanding | 59.07% | 14.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||